Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

The winners of this year’s Canadian science prizes are all based in the United States, where Trump-era cutbacks to research ...

The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

They were told they’d die young. Then a ‘miracle drug’ changed everything — and they have to grapple with what that means - ...

When I was first diagnosed with CF, I wasn’t supposed to live past the age of 8. Then Trikafta gave me the chance for a future I wasn’t prepared for. I’ve built a new life for myself and learned to ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. With the latest approval, Vertex's Kaftrio is now ...

It is also dosed just once a day, while Trikafta needs twice-daily dosing. The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from ...